insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

MNPR · Monopar Therapeutics - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · MNPR

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue$0---------
Cost of Revenue----------
Gross Profit----------
R&D$3.49M-$2.59M$1.73M$1.64M-$984.3K$1.13M$966.1K-
SG&A$1.74M-$1.50M$1.50M$1.58M-$590.6K$657.8K$757.3K-
Total Operating Expenses$5.23M-$4.09M$3.23M$3.22M-$1.57M$1.79M$1.72M-
D&A----------
Operating Income($5.23M)-($4.09M)($3.23M)($3.22M)-($1.57M)($1.79M)($1.72M)-
Interest Expense----------
Income Tax----------
Net Income($3.89M)-($3.44M)($2.45M)($2.62M)-($1.30M)($1.72M)($1.64M)-
EPS - Basic($0.46)-($0.48)($0.35)($0.38)-($0.37)($0.50)($0.50)-
EPS - Diluted----------

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$52.54M$61.83M$127.68M$39.50M$39.71M$45.82M$6.02M$6.12M$7.81M$7.27M
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets$137.74M$140.46M$144.09M$53.75M$55.08M$60.29M$6.07M$7.18M$8.91M$7.33M
Total Assets$137.98M$140.72M$144.20M$53.87M$55.09M$60.29M$6.07M$7.18M$8.91M$7.35M
Current Liabilities$2.46M$2.74M$2.57M$5.25M-----$1.76M
Long-term Debt----------
Total Liabilities$2.59M$2.89M$2.64M$1.66M$1.49M$5.25M$1.12M$1.09M$1.44M$1.76M
Stockholders' Equity$135.39M$137.83M$141.56M$52.20M$53.59M$55.04M$4.95M$6.09M$7.48M$5.59M
Retained Earnings($93.40M)($89.51M)($84.31M)($80.87M)($78.42M)($75.79M)($64.87M)($63.56M)($61.85M)($60.21M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($3.47M)---($5.66M)---($1.66M)-
Investing Cash Flow($5.58M)---($325.8K)---($983.3K)-
Financing Cash Flow($200.2K)---($115.7K)---$3.18M-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-2.8%--2.4%-4.6%-4.8%--21.5%-23.9%-18.4%-
Return on equity-2.9%--2.4%-4.7%-4.9%--26.4%-28.2%-21.9%-
Return on invested capital----------
Liquidity
Current ratio56.0451.3556.1010.23-----4.17
Quick ratio56.0451.3556.1010.23-----4.17
Cash ratio21.3822.6149.717.52-----4.13
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.021.021.021.031.031.101.231.181.191.31
Liabilities / Assets0.020.020.020.030.030.090.180.150.160.24
Efficiency
Asset turnover0.00---------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-62.2%--159.9%-80.8%-86.9%-23.8%23.2%31.7%-
Net income growth (YoY)-48.3%--163.6%-43.0%-59.9%-33.2%22.0%32.6%-
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)152.6%150.4%2761.6%757.1%616.8%885.0%-25.2%-22.3%-16.4%-44.6%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Monopar Therapeutics against the 5 most active filers in the same SIC group.